Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax

Yuwen Wang, Cheng‐Hong Tsai, Chien‐Chin Lin, Feng‐Ming Tien, Yu‐Wen Chen, Hsing-Yu Lin, Ming Yao, Yun‐Chu Lin, Chien‐Ting Lin, Chieh‐Lung Cheng, Jih‐Luh Tang, Wen‐Chien Chou, Hsin‐An Hou, Hwei‐Fang Tien